We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-17.58%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$495M
AUM Growth
-$71.6M
Cap. Flow
+$24.8M
Cap. Flow %
5.02%
Top 10 Hldgs %
75.58%
Holding
34
New
4
Increased
11
Reduced
4
Closed
7

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$30.1M
2
CASC
Cascadian Therapeutics, Inc.
CASC
+$22.6M
3
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$17.3M
4
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$8.2M
5
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$4.3M

Top Sells

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$10.4M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$9.68M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$5.98M
4
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$4.53M
5
ATXS
Astria Therapeutics
ATXS
+$2.75M

Sector Composition

Rank Sector Weight
1 Healthcare 62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACHV icon
26
Achieve Life Sciences
ACHV
$647M
– –
-464
Closed -$2.38M
ATXS
27
DELISTED
Astria Therapeutics
ATXS
– –
-3,750
Closed -$2.75M
EXEL icon
28
Exelixis
EXEL
$14.1B
– –
-2,766,152
Closed -$10.4M
ATYR
29
aTyr Pharma
ATYR
$47.1M
– –
-9,623
Closed -$2.5M
SGEN
30
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-200,000
Closed -$9.68M
FPRX
31
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-240,597
Closed -$5.98M
AKAO
32
DELISTED
Achaogen Inc
AKAO
– –
-106,700
Closed -$643K
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2015 Portfolio in Review

As of Q3 2015, BVF Inc held 34 positions worth $495M, down 13% from $567M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

BVF Inc deployed $24.8M of net new capital in Q3 2015, opening 4 new positions and adding to 11 existing holdings. Its largest new stake was CTI BioPharma Corp. (DE) Common Stock: 1,000,000 shares worth $14.6M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 62% a quarter earlier.

On the sell side, the largest reduction was Concert Pharmaceuticals, Inc., an estimated $4.53M trimmed.

  • BVF Inc's largest Q3 2015 buy was CTI BioPharma Corp. (DE) Common Stock: 1,000,000 shares worth $14.6M.
  • BVF Inc added most to Ironwood Pharmaceuticals in Q3 2015, an estimated $30.1M increase.
  • BVF Inc's biggest Q3 2015 reduction was Concert Pharmaceuticals, Inc., cutting an estimated $4.53M.
  • BVF Inc fully exited Exelixis in Q3 2015, selling an estimated $10.4M.
  • BVF Inc's ten largest holdings make up 76% of its $495M portfolio in Q3 2015.
  • BVF Inc opened 4 new positions and closed 7 in Q3 2015.
  • BVF Inc's portfolio value fell 13% quarter-over-quarter to $495M.

Based on BVF Inc's 13F filing for Q3 2015, filed 16 Nov 2015.